Roivant Sciences(ROIV) - 2026 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported a non-GAAP net loss of $167 million for the quarter, with R&D expenses at $165 million and G&A expenses at $175 million [30] - The company maintains a strong cash position with $4.5 billion in consolidated cash, providing ample capital to reach profitability [30] Business Line Data and Key Metrics Changes - The NDA for brepocitinib in dermatomyositis has been submitted, and the phase 2b study for 1402 in D2T-RA has fully enrolled [6][7] - The phase 2 study for mosliciguat in PH-ILD has also fully enrolled, with top-line data expected in the second half of the year [7][8] Market Data and Key Metrics Changes - The company is targeting a large addressable patient population for brepocitinib, particularly in orphan inflammatory diseases with high unmet needs [25][36] - The potential market for cutaneous sarcoidosis is estimated to be slightly smaller than dermatomyositis, with around 40,000 eligible patients [79] Company Strategy and Development Direction - The company is focused on expanding the development of brepocitinib into additional indications, emphasizing its potential as a first-in-class therapy for sarcoidosis [35][36] - The company plans to leverage insights from the phase 2 study to inform the design of the phase 3 trial, aiming for a similar size and endpoint duration [79] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the strong phase 2 data for brepocitinib, highlighting its potential to address significant patient needs [25][36] - The company anticipates a busy year ahead with multiple pivotal study readouts and potential commercial launches [30][31] Other Important Information - The jury trial against Moderna is scheduled for March 9, with recent favorable decisions regarding summary judgment [29] - The company is exploring further development opportunities for brepocitinib, including other forms of sarcoidosis and related conditions [35][36] Q&A Session Summary Question: What are the further development opportunities for brepocitinib? - Management is enthusiastic about expanding brepocitinib's development, particularly in large orphan markets with high unmet needs [35][36] Question: Can you provide more details on the baseline characteristics of the CSAMI numbers? - There were significant differences in baseline characteristics, including disease duration and morphology, which may have influenced the results [42][43] Question: What is the pricing strategy for brepocitinib? - Pricing has not been finalized, but it is expected to be positioned within the orphan drug pricing envelope [48][50] Question: What are the expectations for the phase 3 trial design? - The phase 3 trial is expected to be similar in size to the phase 2 trial, with final details to be discussed with the FDA [58][79] Question: What percentage of patients in the Beacon study had organ involvement? - Approximately 60% of patients had pulmonary involvement, and exploratory endpoints related to organ involvement were collected but not analyzed yet [83][84]